Received: 17 August 2020
Accepted: 7 January 2021
First Online: 22 January 2021
Ethics approval and consent to participate
: Approved by the University of Utah Institutional Review Board (IRB_00131618). Consent was obtained for all enrolled (10) patients. Consent was obtained both by written and verbal means. As this trial was performed on patients with confirmed COVID-19, this approach was sanctioned by our IRB iin order to decrease exposure of healthcare and research workers to the coronavirus.
: All patients, within the IRB-approved consent form, acknowledged and agreed to the possibility that the results of the study would be published, but specific data would be de-identified.
: Drs. Pierce and Phillips are members of the Department of Medicine and administratively direct the Center for Translational and Regenerative Medicine (CTRM) where the human amniotic fluid is processed and subsequently delivered for clinical use. The CTRM has a number of patents with the University of Utah with regards to the utilization of human amniotic fluid for other disease processes (for example, graft versus host disease). The remaining authors have no competing interests.